Sale!

TNNI3 Gene Cardiomyopathy familial restrictive type 1 Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The “TNNI3 Gene Cardiomyopathy Familial Restrictive Type 1 Genetic Test” is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the TNNI3 gene, which are associated with familial restrictive cardiomyopathy type 1 (RCM1). This form of cardiomyopathy is characterized by the heart muscle becoming rigid, limiting the heart’s ability to fill properly with blood during the relaxation phase, which can lead to heart failure and other serious complications.

This test is crucial for individuals with a family history of RCM1 or who exhibit symptoms suggestive of restrictive cardiomyopathy, as it can confirm the diagnosis and allow for early intervention and management of the condition. The test involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed for specific genetic mutations in the TNNI3 gene.

The cost of the test is 4400 AED, reflecting the specialized nature of the genetic analysis and the expertise required to interpret the results. By identifying the genetic basis of the condition, this test not only aids in the diagnosis and treatment of the individual tested but also provides valuable information for family members who may be at risk, enabling them to make informed decisions about their health and preventive care.

Description

TNNI3 Gene Cardiomyopathy Familial Restrictive Type 1 Genetic Test

Components: TNNI3 Gene Cardiomyopathy familial restrictive type 1 Genetic Test

Price: 4400.0 AED

Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card

Report Delivery: 3 to 4 Weeks

Method: NGS Technology

Test Type: Cardiovascular Pneumology Disorders

Doctor: Cardiologist

Test Department: Genetics

Pre Test Information: Clinical History of Patient who is going for TNNI3 Gene Cardiomyopathy, familial restrictive type 1 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with TNNI3 Gene Cardiomyopathy, familial restrictive type 1 NGS Genetic DNA Test gene TNNI3

Test Details: TNNI3 gene cardiomyopathy, familial restrictive type 1 is a genetic disorder that affects the heart muscle. It is characterized by the development of restrictive cardiomyopathy, which is a condition where the heart muscle becomes stiff and cannot relax properly, leading to impaired filling of the heart chambers. The TNNI3 gene is responsible for providing instructions for the production of a protein called cardiac troponin I. This protein is involved in regulating the contraction and relaxation of the heart muscle. Mutations in the TNNI3 gene can disrupt the normal function of the protein, leading to the development of cardiomyopathy.

NGS (Next-Generation Sequencing) genetic testing is a method used to analyze a person’s DNA to identify any mutations or changes in the TNNI3 gene that may be associated with familial restrictive cardiomyopathy. This type of testing can provide valuable information for diagnosis, prognosis, and treatment planning for individuals and families affected by this genetic disorder.

Genetic testing for TNNI3 gene cardiomyopathy, familial restrictive type 1 can help identify individuals who are at risk of developing the condition, even before symptoms appear. It can also help determine the inheritance pattern of the disorder within a family and provide information for family planning.

It is important to note that genetic testing for TNNI3 gene cardiomyopathy, familial restrictive type 1 should be conducted by a qualified healthcare professional or genetic counselor, who can provide guidance on the implications of the test results and help individuals and families make informed decisions regarding their healthcare.

Test Name	TNNI3 Gene Cardiomyopathy familial restrictive type 1 Genetic Test
Components
Price	4400.0 AED
Sample Condition	Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery	3 to 4 Weeks
Method	NGS Technology
Test type	Cardiovascular Pneumology Disorders
Doctor	Cardiologist
Test Department:	Genetics
Pre Test Information	Clinical History of Patient who is going for TNNI3 Gene Cardiomyopathy, familial restrictive type 1 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with TNNI3 Gene Cardiomyopathy, familial restrictive type 1 NGS Genetic DNA Test gene TNNI3
Test Details	TNNI3 gene cardiomyopathy, familial restrictive type 1 is a genetic disorder that affects the heart muscle. It is characterized by the development of restrictive cardiomyopathy, which is a condition where the heart muscle becomes stiff and cannot relax properly, leading to impaired filling of the heart chambers. The TNNI3 gene is responsible for providing instructions for the production of a protein called cardiac troponin I. This protein is involved in regulating the contraction and relaxation of the heart muscle. Mutations in the TNNI3 gene can disrupt the normal function of the protein, leading to the development of cardiomyopathy. NGS (Next-Generation Sequencing) genetic testing is a method used to analyze a person’s DNA to identify any mutations or changes in the TNNI3 gene that may be associated with familial restrictive cardiomyopathy. This type of testing can provide valuable information for diagnosis, prognosis, and treatment planning for individuals and families affected by this genetic disorder. Genetic testing for TNNI3 gene cardiomyopathy, familial restrictive type 1 can help identify individuals who are at risk of developing the condition, even before symptoms appear. It can also help determine the inheritance pattern of the disorder within a family and provide information for family planning. It is important to note that genetic testing for TNNI3 gene cardiomyopathy, familial restrictive type 1 should be conducted by a qualified healthcare professional or genetic counselor, who can provide guidance on the implications of the test results and help individuals and families make informed decisions regarding their healthcare.